Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

Immuno-oncology drug developer iTeos Therapeutics (NASDAQ:ITOS) on Monday said it has entered into an agreement to be acquired by Concentra Biosciences for $10.047 in cash per share plus a contingent ...

US biotech iTeos Therapeutics yesterday announced that it has entered into a definitive merger agreement Concentra ...

On July 7, 2025, iTeos Therapeutics, Inc. (NASDAQ:ITOS) stock closed at $10.07 per share, with a market capitalization of $385.417 million.

We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks ...

Based on the results, iTeos and GSK are stopping all ongoing trials of belrestotug, including an ongoing Phase 3 study in lung cancer. iTeos is “taking immediate steps to preserve capital” as ...

Turning to iTeos Therapeutics' balance sheet, the company had cash and cash equivalents of $216.2M, short-term investments of $383.0M, and long-term investments of $78.3M as of June 30, 2023.

“As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we’re excited to welcome Dr. Feltquate as Chief Medical Officer,” said Michel ...

iTeos Therapeutics Price Performance NASDAQ ITOS opened at $7.50 on Friday. The firm has a market capitalization of $286.46 million, a P/E ratio of -2.38 and a beta of 1.43. iTeos Therapeutics has ...

ITeos may face some questions on the safety of combining the two medicines, which both ramp up the body’s immune attack on tumors. Three patients in the trial died from immune-related ...